Skip to content
Screener

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Incyte logo
IncyteINCY
400M0.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$18K0.0%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
500M0.0%
Disc Medicine logo
Disc MedicineIRON
$4K+33.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0-100%

Other financials

Income statement

See full
Revenue$44.7M+259%
Gross profit$41.7M+288%
Operating income-$110.6M+13.0%
Net income-$100.7M+10.1%
EPS (diluted)-$1.69+12.4%

Balance sheet

See full
Cash & equivalents$99.6M+23.2%
Total debt$31.2M-36.1%
Total equity$1.0B-25.1%
Total assets$1.1B-24.7%

Cash flow

See full
Operating cash flow-$57.3M+25.7%
CapEx$1.2M+38.5%
Free cash flow-$58.5M+25.0%

Valuation

See full
Market cap$1.91B-13.0%
Enterprise value$1.84B-14.8%
P/S19.4×-34.2×

Profitability

See full
Gross margin92%+3.8pp
Operating margin-466.8%-173pp
Net margin-418.2%
FCF margin-371.4%-143pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity0.0×
Current ratio10.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValueOutstanding.

The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:56 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001439222-26-000118
(In thousands, except share and per share data)June 30,2026December 31,2025
Total liabilities82,403104,111
Stockholders’ equity:
Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 125,000,000 shares authorized; 75,821,241 shares issued and 59,604,830 outstanding at June 30, 2026, and 74,665,003 shares issued and 58,448,592 outstanding at December 31, 20257675
Additional paid-in capital2,591,7452,555,037
Accumulated other comprehensive (loss) income(1,795)2,193
Accumulated deficit(761,519)(561,705)
Treasury stock, at cost (16,216,411 shares at June 30, 2026 and December 31, 2025)(802,486)(802,486)

Item 1. Financial Statements (Unaudited)

FAQ

What is Agios Pharmaceuticals's common stock?
Agios Pharmaceuticals (AGIO) reported common stock of $76K in Q2 2026.
How has Agios Pharmaceuticals's common stock changed year-over-year?
Agios Pharmaceuticals's common stock increased by 2.7% year-over-year, from $74K to $76K.
What is the long-term trend for Agios Pharmaceuticals's common stock?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's common stock has grown at a 1.7% compound annual growth rate (CAGR), from $69K to $75K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Agios Pharmaceuticals's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude